Rapid Micro Biosystems Inc. (Class A) (RPID) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Rapid Micro Biosystems Inc. (Class A) (NASDAQ: RPID) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.70 (-4.50% 1D, market cap $36.9M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, RPID ranks #644 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RPID carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HBIO (Harvard Bioscience Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $40.5M) and PRPO (Precipio Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -7.9%, cap $32.4M). Among the 5-stock peer group, RPID leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
Per RPID's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001380106), Rapid Micro Biosystems Inc. (Class A) generated $33.6M in revenue (+19.7% YoY), -$47.1M in net income, and -$31.9M in free cash flow against $74.9M in total assets and $18.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While RPID currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.06) and Max Pain ($0.74) forces dealer call-delta covering toward $5.19.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Rapid Micro Biosystems Inc. (Class A) (RPID) dropped -4.50% to $0.70, trading at 2% of its 52-week range ($0.7 – $4.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
White Brook Capital’s Q3 2026 investor letter expresses cautious optimism. Its Ethical All-Cap Strategy has outperformed, while the Small Cap Strategy has lagged because of execution delays, higher interest rates, and ma
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +19.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RPID today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RPID. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Rapid Micro Biosystems Inc. (Class A) (RPID) ranks #644 by composite RQD confidence (34/100, grade E) and #777 by equity capitalization ($36.9M). Within this direct 5-issuer industry benchmark cohort, RPID leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. HBIO currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with RPID at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RPID
ACTIVE
Rapid Micro Biosystems Inc. (Class A) | E | 34/100 | — | — | -35.0% | -4.50% | $36.9M | Benchmark Subject |
| HBIO Harvard Bioscience Inc. | D | 47/100 | — | 57.7% | -35.0% | -3.37% | $40.5M | /hbio-vs-rpid → |
| PRPO Precipio Inc. | E | 30/100 | — | 44.2% | -7.9% | -1.71% | $32.4M | /prpo-vs-rpid → |
| EYPT EyePoint Inc. | E | 26/100 | — | — | -35.0% | +7.58% | $30.0M | /eypt-vs-rpid → |
| BNGO Bionano Genomics Inc. | E | 29/100 | — | 46.3% | -35.0% | +0.87% | $16.1M | /bngo-vs-rpid → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rapid Micro Biosystems Inc. (Class A) (RPID) reported GAAP revenue of $33.6M (+19.7% vs. FY2024 revenue of $28.1M , and +49.1% cumulative change since FY2023) , GAAP net income of -$47.1M, operating cash flow of -$31.1M, and free cash flow of -$31.9M (+29.9% YoY). On the balance sheet, RPID closed FY2025 with $74.9M in total assets against $18.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $33.6M | -$47.1M | -$31.1M | -$31.9M | $74.9M | $18.9M |
| FY2024 (FY) | 2024-12-31 | $28.1M | -$46.9M | -$44.2M | -$45.5M | $98.2M | $0 |
| FY2023 (FY) | 2023-12-31 | $22.5M | -$52.5M | -$45.1M | -$45.1M | — | — |
As of 2026-11-03, Rapid Micro Biosystems Inc. (Class A) (NASDAQ: RPID) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.70 (-4.50% 1D, market cap $36.9M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, RPID ranks #644 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RPID carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HBIO (Harvard Bioscience Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $40.5M) and PRPO (Precipio Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -7.9%, cap $32.4M). Among the 5-stock peer group, RPID leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
Per RPID's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001380106), Rapid Micro Biosystems Inc. (Class A) generated $33.6M in revenue (+19.7% YoY), -$47.1M in net income, and -$31.9M in free cash flow against $74.9M in total assets and $18.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
RPID last traded at $0.70 (-4.50% on volume of 77,267 shares), positioning the stock -33.96% below its 50-day simple moving average ($1.06) and -68.33% below its 200-day simple moving average ($2.21). Across its 52-week range of $0.70 to $4.94, RPID sits at the 0.0% percentile with a 14-day RSI of 31.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.79).
Rapid Micro Biosystems Inc. (Class A) (RPID) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.70 (-4.50% 1D, market capitalization $36.9M).
Rapid Micro Biosystems Inc. (Class A) is a NASDAQ-listed Health Care issuer in the Biotechnology: Laboratory Analytical Instruments industry. Specific product lines, customer segments, and revenue model details are — The reported revenue figures in the SEC financials indicate an operating business with $33.6M of FY 2025 revenue, but the source does not describe how that revenue is generated.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Rapid Micro Biosystems Inc. (Class A) (RPID) reported $33.6M in annual revenue (up from $28.1M in FY2024, +19.7% YoY) and -$47.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($22.5M revenue, -$52.5M net income) through FY2025, RPID scaled operating cash flow to -$31.1M and free cash flow to -$31.9M, backed by $74.9M in total assets against $18.9M in total debt.
There are no upstream or downstream links, no sector correlations, and no proprietary signals in the source data. Upstream/downstream dependencies: — Sector correlations: — 2nd-order bottlenecks: — The only sector information available is the Health Care / Biotechnology: Laboratory Analytical Instruments classification.
Real-time company headlines, analyst actions, and sector developments for Rapid Micro Biosystems Inc. (Class A) (RPID) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Rapid Micro Biosystems Inc. (Class A) (RPID) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on RPID here at $0.74: Revenue grew from $22.5M in FY 2023 to $33.6M in FY 2025, and the forensic balance sheet pillar scores 11 / 20 on Altman Z 2.5 and Debt/Equity 0.57.. Compare RPID's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Laboratory Analytical Instruments. As long as cash conversion holds up, dips toward $0.70 are getting bought.
@MultipleCompression Shorting a 3/20 institutional whale-flow stock at $0.74 is dangerous when funds are rotating into Health Care.
I respect the product at Rapid Micro Biosystems Inc. (Class A), but the stock at $0.74 is a different story. FY 2025 free cash flow of -$31.9M against $20.0M of cash, with ROIC at -35% and operating margin at -60%, leaves the cash engine pillar at 9 / 20.. FCF yield is 0.0% and RQD sits at 34/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: